Data will be available to researchers studying a wide range of disease states BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the […]
Coronary/Structural Heart
Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders
Organization recognizes the most promising and innovative health startups in New York NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized the company on […]
Paragonix Technologies LUNGguard™ Used in Record Cross-Country Donor Lung Transplant Case
Device enables donor lungs to safely travel unprecedented distance of 4,788 Miles with a total ischemic time of over 13 hours CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest […]
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Aficamten Reduced LVOT Gradients in Patients on Disopyramide With No Instances of Left Ventricular Ejection Fraction Below 50% Findings Support Inclusion of Patients on Disopyramide in SEQUOIA-HCM SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of […]
Englewood Health Receives Prestigious National Certification for Heart Valve Program
Bergen County’s first hospital to earn recognition from the American College of Cardiology for Transcatheter Valve ENGLEWOOD, N.J., Feb. 1, 2022 /PRNewswire/ — Englewood Health has been recognized by the American College of Cardiology (ACC) with the Transcatheter Valve Certification. This mark of distinction reflects the accomplishments of the Structural Heart and […]
Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery
Results Presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons ATLANTA, Jan. 31, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society […]
CARMAT Anticipates Implants of Its Aeson® Artificial Heart to Resume in October 2022
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR): Videoconference in English with Stéphane Piat at 8 pm CET today. To participate, please register by clicking on this link CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic […]
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
NEW YORK and CARLSBAD, Calif., Jan. 31, 2022 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). Pfizer made this decision after a thorough […]
Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling
MILANO, Italy, Jan. 28, 2022 /PRNewswire/ — FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels) setting in motion a crucial trial in the Native Coronary Vessel Treatment domain. TRANSFORM II RCT, determined to […]
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
– The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 – If approved, Jardiance would be the first and only clinically proven treatment approved for all adults with symptomatic chronic heart failure including […]